267 related articles for article (PubMed ID: 31144349)
1. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
[TBL] [Abstract][Full Text] [Related]
2. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.
van der Stoep MYEC; Bertaina A; Ten Brink MH; Bredius RG; Smiers FJ; Wanders DCM; Moes DJAR; Locatelli F; Guchelaar HJ; Zwaveling J; Lankester AC
Br J Haematol; 2017 Dec; 179(5):772-780. PubMed ID: 29048102
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.
Danielak D; Twardosz J; Kasprzyk A; Wachowiak J; Kałwak K; Główka F
Eur J Clin Pharmacol; 2018 Jan; 74(1):79-89. PubMed ID: 28975382
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations.
Rosser SPA; Lee S; Kohli S; Keogh SJ; Chung J; O'Brien T; Fraser C; McLachlan AJ; Shaw PJ; Nath CE
Br J Clin Pharmacol; 2023 Apr; 89(4):1413-1424. PubMed ID: 36369677
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation.
Lawson R; Paterson L; Fraser CJ; Hennig S
Cancer Chemother Pharmacol; 2021 Sep; 88(3):379-391. PubMed ID: 34021809
[TBL] [Abstract][Full Text] [Related]
8. Relationship between exposure to treosulfan and its monoepoxytransformer - An insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation.
Danielak D; Kasprzyk A; Wróbel T; Wachowiak J; Kałwak K; Główka F
Eur J Pharm Sci; 2018 Jul; 120():1-9. PubMed ID: 29705215
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Mohanan E; Panetta JC; Lakshmi KM; Edison ES; Korula A; Na F; Abraham A; Viswabandya A; George B; Mathews V; Srivastava A; Balasubramanian P
Clin Pharmacol Ther; 2018 Sep; 104(3):575-583. PubMed ID: 29247522
[TBL] [Abstract][Full Text] [Related]
10. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
Rosser SPA; Brewer A; Gabriel M; Wong M; Chung J; McLachlan AJ; Nath CE; Keogh SJ; Shaw PJ
Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
[TBL] [Abstract][Full Text] [Related]
11. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.
ten Brink MH; Zwaveling J; Swen JJ; Bredius RG; Lankester AC; Guchelaar HJ
Drug Discov Today; 2014 Oct; 19(10):1572-86. PubMed ID: 24747172
[TBL] [Abstract][Full Text] [Related]
12. Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial.
Chiesa R; Standing JF; Winter R; Nademi Z; Chu J; Pinner D; Kloprogge F; McLellen S; Amrolia PJ; Rao K; Lucchini G; Silva J; Ciocarlie O; Lazareva A; Gennery AR; Doncheva B; Cant AJ; Hambleton S; Flood T; Rogerson E; Devine K; Prunty H; Heales S; Veys P; Slatter M
Clin Pharmacol Ther; 2020 Aug; 108(2):264-273. PubMed ID: 31701524
[TBL] [Abstract][Full Text] [Related]
13. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
[TBL] [Abstract][Full Text] [Related]
14. Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.
Solans BP; Chiesa R; Doncheva B; Prunty H; Veys P; Trocóniz IF; Standing JF
Br J Clin Pharmacol; 2020 Aug; 86(8):1537-1549. PubMed ID: 32077123
[TBL] [Abstract][Full Text] [Related]
15. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
16. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
Główka FK; Romański M; Wachowiak J
Expert Opin Investig Drugs; 2010 Oct; 19(10):1275-95. PubMed ID: 20836619
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation.
Li X; Kalwak K; Beier R; Kehne J; Möller AK; Baumgart J; Beelen DW; Hilger RA; Vora A; Sykora KW
Drug Metab Pharmacokinet; 2023 Oct; 52():100515. PubMed ID: 37481830
[TBL] [Abstract][Full Text] [Related]
18. Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives.
Romański M; Wachowiak J; Główka FK
Clin Pharmacokinet; 2018 Oct; 57(10):1255-1265. PubMed ID: 29557088
[TBL] [Abstract][Full Text] [Related]
19. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation.
Główka FK; Łada MK; Grund G; Wachowiak J
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):569-74. PubMed ID: 17210272
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.
Sandström M; Karlsson MO; Ljungman P; Hassan Z; Jonsson EN; Nilsson C; Ringden O; Oberg G; Bekassy A; Hassan M
Bone Marrow Transplant; 2001 Oct; 28(7):657-64. PubMed ID: 11704788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
